These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23343155)

  • 1. Nanomedicines for HIV therapy.
    Siccardi M; Martin P; McDonald TO; Liptrott NJ; Giardiello M; Rannard S; Owen A
    Ther Deliv; 2013 Feb; 4(2):153-6. PubMed ID: 23343155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral nanoparticles: an extended drug delivery modality.
    Destache CJ; Goede M; Belgum T
    Ther Deliv; 2010 Sep; 1(3):383-6. PubMed ID: 22816141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-drug conjugates and associated carrier strategies for enhanced antiretroviral drug delivery.
    Takalani F; Kumar P; Kondiah PPD; Choonara YE; Pillay V
    Pharm Dev Technol; 2020 Mar; 25(3):267-280. PubMed ID: 31744408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New hope for eradication of HIV from the body: the role of polymeric nanomedicines in HIV/AIDS pharmacotherapy.
    Lenjisa JL; Woldu MA; Satessa GD
    J Nanobiotechnology; 2014 Mar; 12():9. PubMed ID: 24655921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies.
    Edagwa BJ; Zhou T; McMillan JM; Liu XM; Gendelman HE
    Curr Med Chem; 2014; 21(36):4186-98. PubMed ID: 25174930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nano-Medicine as a Newly Emerging Approach to Combat Human Immunodeficiency Virus (HIV).
    Saravanan M; Asmalash T; Gebrekidan A; Gebreegziabiher D; Araya T; Hilekiros H; Barabadi H; Ramanathan K
    Pharm Nanotechnol; 2018; 6(1):17-27. PubMed ID: 29424324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymeric nanoparticles for enhancing antiretroviral drug therapy.
    Govender T; Ojewole E; Naidoo P; Mackraj I
    Drug Deliv; 2008 Nov; 15(8):493-501. PubMed ID: 18720133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral bioavailability: issues and solutions via nanoformulations.
    Pathak K; Raghuvanshi S
    Clin Pharmacokinet; 2015 Apr; 54(4):325-57. PubMed ID: 25666353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advancements in nano-enabled therapeutics for neuroHIV management.
    Kaushik A; Jayant RD; Nair M
    Int J Nanomedicine; 2016; 11():4317-25. PubMed ID: 27621624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive insights into herbal P-glycoprotein inhibitors and nanoformulations for improving anti-retroviral therapy efficacy.
    Jain P; Parikh S; Patel P; Shah S; Patel K
    J Drug Target; 2024 Sep; 32(8):884-908. PubMed ID: 38748868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting.
    Gupta U; Jain NK
    Adv Drug Deliv Rev; 2010 Mar; 62(4-5):478-90. PubMed ID: 19913579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines.
    Greco F; Vicent MJ
    Adv Drug Deliv Rev; 2009 Nov; 61(13):1203-13. PubMed ID: 19699247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in antiretroviral drug delivery using nanotechnology.
    Mallipeddi R; Rohan LC
    Int J Nanomedicine; 2010 Aug; 5():533-47. PubMed ID: 20957115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small magnetite antiretroviral therapeutic nanoparticle probes for MRI of drug biodistribution.
    Guo D; Li T; McMillan J; Sajja BR; Puligujja P; Boska MD; Gendelman HE; Liu XM
    Nanomedicine (Lond); 2014 Jul; 9(9):1341-52. PubMed ID: 23905578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Data Analytics Approach for Rational Design of Nanomedicines with Programmable Drug Release.
    Mullis AS; Broderick SR; Binnebose AM; Peroutka-Bigus N; Bellaire BH; Rajan K; Narasimhan B
    Mol Pharm; 2019 May; 16(5):1917-1928. PubMed ID: 30973741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Penetration of polymeric nanoparticles loaded with an HIV-1 inhibitor peptide derived from GB virus C in a vaginal mucosa model.
    Ariza-Sáenz M; Espina M; Bolaños N; Calpena AC; Gomara MJ; Haro I; García ML
    Eur J Pharm Biopharm; 2017 Nov; 120():98-106. PubMed ID: 28842284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Versatile iron-catechol-based nanoscale coordination polymers with antiretroviral ligand functionalization and their use as efficient carriers in HIV/AIDS therapy.
    Solórzano R; Tort O; García-Pardo J; Escribà T; Lorenzo J; Arnedo M; Ruiz-Molina D; Alibés R; Busqué F; Novio F
    Biomater Sci; 2018 Dec; 7(1):178-186. PubMed ID: 30507990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enabled clinical use of an HIV-1 attachment inhibitor through drug delivery.
    Timmins P; Brown J; Meanwell NA; Hanna GJ; Zhu L; Kadow JF
    Drug Discov Today; 2014 Sep; 19(9):1288-93. PubMed ID: 24727410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological rationale for the design of polymeric anti-cancer nanomedicines.
    Zhou Y; Kopeček J
    J Drug Target; 2013 Jan; 21(1):1-26. PubMed ID: 23009337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noncovalent PEG Coating of Nanoparticle Drug Carriers Improves the Local Pharmacokinetics of Rectal Anti-HIV Microbicides.
    Nunes R; Araújo F; Barreiros L; Bártolo I; Segundo MA; Taveira N; Sarmento B; das Neves J
    ACS Appl Mater Interfaces; 2018 Oct; 10(41):34942-34953. PubMed ID: 30234288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.